Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3401
PUT
Adient
ADNT
$1.57B
| $2.13M | ﹤0.01% |
27,000
+4,000
| +17% | +$323K |
|
3402
CALL
Acadia Pharmaceuticals
ACAD
$4.87B
| $2.12M | ﹤0.01% |
70,500
+2,900
| +4% | +$92.7K |
|
3403
CALL
Invesco DB Agriculture Fund
DBA
$1.24B
| $2.12M | ﹤0.01% |
113,100
+3,600
| +3% | +$68.2K |
|
3404
State Street Materials Select Sector SPDR ETF
XLB
$8.6B
| $2.12M | ﹤0.01% |
69,964
-148,076
| -68% | -$4.36M |
|
3405
PUT
Cal-Maine
CALM
$3.8B
| $2.12M | ﹤0.01% |
47,600
+11,200
| +31% | +$499K |
|
|
ACHN
3406
DELISTED
Achillion Pharmaceuticals
ACHN
| $2.12M | ﹤0.01% |
734,644
+633,626
| +627% | +$2.3M |
|
|
CVRR
3407
DELISTED
CVR Refining, LP
CVRR
| $2.11M | ﹤0.01% |
+127,756
| New | +$1.58M |
|
3408
First Majestic Silver
AG
$9.49B
| $2.11M | ﹤0.01% |
313,223
+137,014
| +78% | +$945K |
|
3409
PUT
Opko Health
OPK
$1.03B
| $2.11M | ﹤0.01% |
430,900
+217,200
| +102% | +$1.26M |
|
|
MGP
3410
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
| $2.11M | ﹤0.01% |
72,327
-155,300
| -68% | -$4.55M |
|
3411
PUT
Methanex
MEOH
$4.34B
| $2.11M | ﹤0.01% |
34,800
+7,300
| +27% | +$384K |
|
3412
CALL
Omega Healthcare
OHI
$14.1B
| $2.11M | ﹤0.01% |
76,500
-10,800
| -12% | -$312K |
|
3413
PUT
Zebra Technologies
ZBRA
$17.8B
| $2.11M | ﹤0.01% |
20,300
+8,900
| +78% | +$968K |
|
3414
Associated Banc-Corp
ASB
$6.11B
| $2.11M | ﹤0.01% |
82,927
+38,238
| +86% | +$956K |
|
3415
Celldex Therapeutics
CLDX
$3.29B
| $2.1M | ﹤0.01% |
49,302
-60,659
| -55% | -$2.6M |
|
3416
PUT
Lennar Class A
LEN
$20.9B
| $2.1M | ﹤0.01% |
34,296
-22,855
| -40% | -$1.3M |
|
3417
PUT
Televisa
TV
$1.53B
| $2.1M | ﹤0.01% |
112,500
+50,700
| +82% | +$1.05M |
|
|
ABMD
3418
CALL
DELISTED
Abiomed Inc
ABMD
| $2.1M | ﹤0.01% |
11,200
+1,100
| +11% | +$205K |
|
|
SNV
3419
CALL
DELISTED
Synovus
SNV
| $2.1M | ﹤0.01% |
43,700
+20,600
| +89% | +$976K |
|
3420
Exponent
EXPO
$3.19B
| $2.09M | ﹤0.01% |
58,882
+35,808
| +155% | +$1.31M |
|
|
ONCE
3421
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $2.09M | ﹤0.01% |
40,700
+25,700
| +171% | +$1.85M |
|
3422
Icon
ICLR
$12.6B
| $2.09M | ﹤0.01% |
+18,651
| New | +$2.15M |
|
|
CYBR
3423
CALL
DELISTED
CyberArk
CYBR
| $2.09M | ﹤0.01% |
50,500
-9,000
| -15% | -$394K |
|
3424
CALL
Quest Diagnostics
DGX
$25.9B
| $2.09M | ﹤0.01% |
21,200
-21,900
| -51% | -$2.08M |
|
|
AERI
3425
DELISTED
Aerie Pharmaceuticals
AERI
| $2.08M | ﹤0.01% |
34,903
-169,418
| -83% | -$10.3M |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.